74-55-5

74-55-5 structure
74-55-5 structure
  • Name: Ethambutol
  • Chemical Name: ethambutol
  • CAS Number: 74-55-5
  • Molecular Formula: C10H24N2O2
  • Molecular Weight: 204.310
  • Catalog: API Synthetic anti-infective drugs Anti-tuberculosis leprosy
  • Create Date: 2018-07-05 13:14:30
  • Modify Date: 2025-08-20 19:24:05
  • Ethambutol is a bacteriostatic antimycobacterial agent, which obstructs the formation of cell wall by inhibiting arabinosyl transferases.Target: AntibacterialEthambutol directly affects two polymers, arabinogalactan (AG) and lipoarabinomannan (LAM) in Mycobacterium smegmatis. In M. smegmatis, Ethambutol inhibits synthesis of arabinan completely and inhibits AG synthesis most likely as a consequence of this; more than 50% of the cell arabinan is released from the bacteria following Ethambutol treatment, whereas no galactan is released. Ethambutol main targets against embB gene product in M. avium. Ethambutol induces 60% changes in the embB gene in M. tuberculosis resistant mutants [1]. Ethambutol is effective against actively growing microorganisms of the genus Mycobacterium, including M. tuberculosis. Nearly all strains of M. tuberculosis and M. kansasii as well as a number of strains of the M. aviumcomplex (MAC) are sensitive to Ethambutol. [1] Ethambutol is potency against M. tuberculosis (H37Rv) with MIC of 0.5 μg/mL in vitro [2]. Ethambutol is efficient on treatment of mycobacterial-infected macrophages. When M. tuberculosis infected macrophages are treated with 6 μg/mL Ethambutol, the log CFUs following treatment for 3 days is 4.17, while value in control group is 4.8. The MICs for M. avium (MTCC 1723) and M. smegmatis (MTCC 6) are 15 μg/mL and 0.18 μg/mL, respectively. Ethambutol is efficient in animal model. 100 mg/kg Ethambutol given orally 15 days post i.v. infection 1 ×/week for 5 weeks, induces a lower log CFU compared with untreatment (4.59 vs 5.07) [3].

Name ethambutol
Synonyms (S,S)-Et,Et-FerroTANE
(+)-1,1'-BIS[(2R,4R)-2,4-DIETHYLPHOSPHONATO]FERROCENE
R,R-Et-FerroTANE
(S,S)-2,2'-(ethylenediimino)di-1-butanol
(R,R)-ET-FERROTANE(TM)
(+)-1,1'-BIS((2R,4R)-2,4-DIETHYLPHOSPHOTANO)FERROCENE
(S,S)-1-[1-(DI-TERT-BUTYLPHOSPHINO)ETHYL]-2-(DIPHENYLPHOSPHINO)FERROCENE
Et-Ferrotane
1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-
Ethambutol
(S)-(+)-1-[(R)-2-(DIPHENYLPHOSPHINO)FERROCENYL]ETHYLDI-T-BUTYLPHOSPHINE
2,2'-(1,2-Ethanediyldiimino)di(1-butanol)
JOSIPHOS SL-J002-2
Description Ethambutol is a bacteriostatic antimycobacterial agent, which obstructs the formation of cell wall by inhibiting arabinosyl transferases.Target: AntibacterialEthambutol directly affects two polymers, arabinogalactan (AG) and lipoarabinomannan (LAM) in Mycobacterium smegmatis. In M. smegmatis, Ethambutol inhibits synthesis of arabinan completely and inhibits AG synthesis most likely as a consequence of this; more than 50% of the cell arabinan is released from the bacteria following Ethambutol treatment, whereas no galactan is released. Ethambutol main targets against embB gene product in M. avium. Ethambutol induces 60% changes in the embB gene in M. tuberculosis resistant mutants [1]. Ethambutol is effective against actively growing microorganisms of the genus Mycobacterium, including M. tuberculosis. Nearly all strains of M. tuberculosis and M. kansasii as well as a number of strains of the M. aviumcomplex (MAC) are sensitive to Ethambutol. [1] Ethambutol is potency against M. tuberculosis (H37Rv) with MIC of 0.5 μg/mL in vitro [2]. Ethambutol is efficient on treatment of mycobacterial-infected macrophages. When M. tuberculosis infected macrophages are treated with 6 μg/mL Ethambutol, the log CFUs following treatment for 3 days is 4.17, while value in control group is 4.8. The MICs for M. avium (MTCC 1723) and M. smegmatis (MTCC 6) are 15 μg/mL and 0.18 μg/mL, respectively. Ethambutol is efficient in animal model. 100 mg/kg Ethambutol given orally 15 days post i.v. infection 1 ×/week for 5 weeks, induces a lower log CFU compared with untreatment (4.59 vs 5.07) [3].
Related Catalog
References

[1]. Ethambutol. Tuberculosis (Edinb), 2008. 88(2): p. 102-5.

[2]. Rastogi, N., V. Labrousse, and K.S. Goh, In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain

[3]. Kaur, D. and G.K. Khuller, In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria. Int J Antimicrob Agents, 2001. 17(1): p. 51-5.

Density 1.0±0.1 g/cm3
Boiling Point 345.3±22.0 °C at 760 mmHg
Melting Point 199 - 204ºC
Molecular Formula C10H24N2O2
Molecular Weight 204.310
Flash Point 113.7±12.9 °C
Exact Mass 204.183777
PSA 64.52000
LogP -0.05
Vapour Pressure 0.0±1.7 mmHg at 25°C
Index of Refraction 1.478
Storage condition 2-8℃

CHEMICAL IDENTIFICATION

RTECS NUMBER :
EL3640000
CHEMICAL NAME :
1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (R)-
CAS REGISTRY NUMBER :
74-55-5
LAST UPDATED :
199706
DATA ITEMS CITED :
8
MOLECULAR FORMULA :
C10-H24-N2-O2
MOLECULAR WEIGHT :
204.36
WISWESSER LINE NOTATION :
Q1Y2&M2MY2&1Q -D

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
900 mg/kg/60D-I
TOXIC EFFECTS :
Liver - jaundice, cholestatic
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 292,866,1986
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
600 mg/kg
TOXIC EFFECTS :
Peripheral Nerve and Sensation - structural change in nerve or sheath Behavioral - changes in motor activity (specific assay) Kidney, Ureter, Bladder - other changes in urine composition
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 2,1105,1976
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
1200 mg/kg
TOXIC EFFECTS :
Skin and Appendages - dermatitis, other (after systemic exposure) Immunological Including Allergic - anaphylaxis
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 2,1105,1976
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
8700 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold
REFERENCE :
DPHFAK Dissertationes Pharmaceuticae et Pharmacologicae. (Warsaw, Poland) V.18-24, 1966-72. For publisher information, see PJPPAA. Volume(issue)/page/year: 23,463,1971
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1075 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold
REFERENCE :
DPHFAK Dissertationes Pharmaceuticae et Pharmacologicae. (Warsaw, Poland) V.18-24, 1966-72. For publisher information, see PJPPAA. Volume(issue)/page/year: 23,463,1971
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
240 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold
REFERENCE :
DPHFAK Dissertationes Pharmaceuticae et Pharmacologicae. (Warsaw, Poland) V.18-24, 1966-72. For publisher information, see PJPPAA. Volume(issue)/page/year: 23,463,1971
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Mammal - species unspecified
DOSE/DURATION :
890 mg/kg
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - other changes
REFERENCE :
NYKZAU Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. (Nippon Yakuri Gakkai, c/o Kyoto Daigaku Igakubu Yakurigaku Kyoshitsu, Konoe-cho, Yoshida, Sakyo-ku, Kyoto 606, Japan) V.40- 1944- Volume(issue)/page/year: 63(3),114S,1967
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - species unspecified
DOSE/DURATION :
350 mg/kg
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - other changes
REFERENCE :
NYKZAU Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. (Nippon Yakuri Gakkai, c/o Kyoto Daigaku Igakubu Yakurigaku Kyoshitsu, Konoe-cho, Yoshida, Sakyo-ku, Kyoto 606, Japan) V.40- 1944- Volume(issue)/page/year: 63(3),114S,1967
HS Code 2922191000

~%

74-55-5 structure

74-55-5

Literature: Journal of the American Chemical Society, , vol. 122, # 25 p. 5968 - 5976

~%

74-55-5 structure

74-55-5

Literature: Journal of the American Chemical Society, , vol. 122, # 25 p. 5968 - 5976

~78%

74-55-5 structure

74-55-5

Literature: Kotkar, Shriram P.; Sudalai, Arumugam Tetrahedron Asymmetry, 2006 , vol. 17, # 11 p. 1738 - 1742

~%

74-55-5 structure

74-55-5

Literature: Doklady Chemistry, , vol. 145, p. 597 - 600 Doklady Akademii Nauk SSSR, , vol. 145, p. 332 - 335

~%

74-55-5 structure

74-55-5

Literature: Justus Liebigs Annalen der Chemie, , p. 1455 - 1464

~%

74-55-5 structure

74-55-5

Literature: Justus Liebigs Annalen der Chemie, , p. 1455 - 1464

~%

74-55-5 structure

74-55-5

Literature: Tetrahedron, , vol. 58, # 49 p. 9765 - 9767

~%

74-55-5 structure

74-55-5

Literature: Journal of the American Chemical Society, , vol. 83, p. 2212 - 2213

~%

74-55-5 structure

74-55-5

Literature: Journal of Medicinal and Pharmaceutical Chemistry, , vol. 5, p. 835 - 845
HS Code 2922191000
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.